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OBJECTIVE—To test the hypothesis that polymorphic variation
in the paternally transmitted fetal IGF2 gene is associated with
maternal glucose concentrations in the third trimester of preg-
nancy.
RESEARCH DESIGN AND METHODS—A total of 17 haplo-
type tag single nucleotide polymorphisms in the IGF2 gene re-
gion were genotyped in 1,160 mother/partner/offspring trios from
the prospective Cambridge Baby Growth Study (n = 845 trios)
and the retrospective Cambridge Wellbeing Study (n = 315 trios)
(3,480 samples in total). Associations were tested between inferred
parent-of-origin fetal alleles, z scores of maternal glucose concen-
trations 60 min. after an oral glucose load performed at week 28
of pregnancy, and offspring birth weights.
RESULTS—Using the minimum P value test, paternally trans-
mitted fetal IGF2 polymorphisms were associated with maternal
glucose concentrations; speciﬁcally, paternally transmitted fetal
rs6578987 (P = 0.006), rs680 (P = 0.01), rs10770125 (P = 0.0002),
and rs7924316 (P = 0.01) alleles were associated with increased
maternal glucose concentrations in the third trimester of preg-
nancy and placental IGF-II contents at birth (P = 0.03). In con-
trast, there were no associations between maternal glucose
concentrations and maternal or maternally transmitted fetal
IGF2 genotypes.
CONCLUSIONS—Polymorphic variation in paternally transmit-
ted fetal IGF2 is associated with increased maternal glucose con-
centrations in pregnancy and could potentially alter the risk of
gestational diabetes in the mother. The association may be at
least partially mediated by changes in placental IGF2 expression.
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A lmost 20 years ago it was hypothesized thatpolymorphic variation in the fetal genome, inparticular in fetal growth genes, could lead toalterations in maternal metabolism in preg-
nancy (1). More recently, we suggested that in addition to
the risk associated with polymorphic variation in the
mother’s genes, which could affect her glucose concen-
trations (2), fetal genomic variation could also alter a
mother’s risk of developing gestational diabetes mellitus
(GDM) (3). Many well-characterized fetal growth genes are
imprinted (4), meaning that they are expressed from only
either the paternally or the maternally transmitted copy,
depending on the gene in question and the stage of devel-
opment. Haig’s kinship, or conﬂict hypothesis (5,6), sug-
gests that paternally expressed fetal imprinted genes will
tend to increase fetal growth, whereas maternally ex-
pressed genes will tend to restrain it. This is thought to be
achieved through modifying fetal and placental nutritional
demand and supply (7), potentially including altering ma-
ternal glucose concentrations (1,3).
We recently tested our hypothesis (3) in phenotypically
wild type pregnant mice that were carrying pups that had
a targeted 13 kb genetic region disrupted, which included
the imprinted H19 gene and Igf2 control element (8). Af-
fected pups in this model are born ;30% heavier than
unaffected litter mates (9), principally as a result of biallelic
Igf2 expression resulting from the disruption of its control
element (10). Consistent with our hypothesis, we found that
intraperitoneal glucose tolerance tests indicated that mice
carrying knockout offspring had increased circulating glu-
cose concentrations in late pregnancy in comparison with
those of genetically matched controls (8).
In humans, the IGF2 gene is located in a region rich in
imprinted genes (11p15.5). The IGF2 gene comprises nine
exons (codons 7–9 being coding) and four promoters,
spanning a region of ;30 kb (11). Several different RNA
molecules are formed upon transcription of the gene within
the coding region plus one of the various 59-untranslated
regions arising from exons 1–6. The different transcripts are
expressed according to their tissue and the stage of de-
velopment (11). In the human fetus and placenta, IGF2 is
imprinted such that only the paternally transmitted copy
of the gene is expressed. Cord blood concentrations of its
protein product, IGF-II, are associated with birth weight
(12). In contemporary birth cohorts, we found that in ﬁrst
pregnancies, cord blood IGF-II concentrations were also
associated with a polymorphic variant in H19, another
imprinted gene in the 11p15.5 region in humans and one
that may regulate IGF2 gene expression (6) when trans-
mitted from the mother to the fetus (13). This H19 single
nucleotide polymorphism (SNP) was also associated with
maternal glucose concentrations, suggesting that our
ﬁndings in mice (8) may be relevant to humans.
The current study was designed to see if the results from
our mouse model (8), indicating that functional variation
in the fetal IGF2 gene alters maternal glucose concentrations
in pregnancy, could also be observed in an analogous man-
ner in humans. Speciﬁcally, we tested the hypothesis that
polymorphic variation in paternally transmitted fetal IGF2
is associated with alterations in maternal glucose concen-
trations at week 28 of pregnancy and offspring birth weight.
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RESEARCH DESIGN AND METHODS
Cohorts and assessment of glucose concentrations. The Cambridge Baby
Growth Study (prospective and longitudinal) recruited mothers (and their
partners and offspring) attending ultrasound clinics during early pregnancy at
the Rosie Maternity Hospital, Cambridge, U.K., between 2001 and 2009 (14,15).
At 28 weeks of gestation, all the mothers underwent a 75-g oral glucose tol-
erance test after an overnight fast. Venous blood was collected after fasting
and at 60 min. after the glucose load for the measurement of plasma glucose
concentrations (using a routine glucose oxidase–based method). Capillary
blood glucose measurements were made at 0, 30, 60, 90, and 120 min using an
Abbott Freestyle Mini (Abbott Diagnostics, Maidenhead, U.K.). Blood and/or
mouth swab samples for DNA extraction were collected from the father and
the offspring after its birth. In total, 845 DNA trios were collected from the
families of 1,074 mothers recruited to the study for whom oral glucose toler-
ance test data were available. In this cohort, 96.9% of the offspring were of
Caucasian ethnicity, 0.8% were of mixed race, 0.6% were black (African or
Caribbean), 0.8% were Oriental, and 0.9% were Indo-Asian.
The Cambridge Wellbeing Study (retrospective) recruited mothers, fathers,
and children where the pregnant mother had delivered a full-term, singleton
baby at the Rosie Maternity Hospital, Cambridge, U.K., between the years 1999
to 2000 (13,14). Routinely collected clinical data were available on offspring
birth weight and mother’s whole blood glucose levels measured 60 min after
the oral consumption of 50-g glucose at 27 to 29 weeks of gestation. Exclusion
criteria were maternal hypertension and treatment for diabetes during preg-
nancy. In this cohort, all the offspring were of Caucasian ethnicity. We sought
permission from the mother’s general practitioner to approach the mother,
partner, and child to collect their DNA sample by postal mouth swab kits. In
total, 315 DNA trios were collected out of a total of 563 women who con-
sented; glucose concentrations were available from .3,000 women, many of
whom were not approached to provide consent for genetic analysis. Tables 1
and 2 show characteristics of the study participants from the two cohorts.
Ethical approval. Both the Cambridge Baby Growth Study and the Cambridge
Wellbeing Study were approved by the local ethics committee, Addenbrooke’s
Hospital, Cambridge, U.K. Written informed consent was obtained from the
parents, including consent for inclusion of their infants in the study.
Measurement of birth weight. For both cohorts, we used the routine mea-
surement of birth weight made at delivery by midwives and recorded in the
hospital notes. Approximately 420 of the mothers gave birth during the daytime,
and their term placentas were collected and processed within an hour of
delivery, snap frozen, and then stored at220°C until aliquots were removed for
protein and/or RNA extraction.
SNP selection. A total of 17 IGF2 region (i.e., IGF2-INS-TH cluster) SNPs
were selected based on the 11 haplotype tag SNPs identiﬁed by Rodríguez
et al. (16), plus 6 SNPs from the Centre d’Etude du Polymorphisme Humain
(CEU) population (Utah residents with ancestry from Northern and Western
Europe) of the HapMap Project Build 36 using Haploview (17) (Hapmap
accessed 19 January 2010). We force included the 11 Rodríguez et al. SNPs,
using pairwise tagging r2 .0.8 and a minor allele frequency of at least 0.2 as
the acceptance criteria (Fig. 1), and identiﬁed 5 haplotype blocks tagged by 14
SNPs (Table 3 and Supplementary Fig. 1). Three of the SNPs used by Rodríguez
et al. were not required to deﬁne these haplotype blocks but were included for
genotyping.
Genotyping. Genomic DNA was extracted from blood samples or mouth
swabs using an Autopure LS Machine (Qiagen Ltd., Crawley, U.K.). Of the 17
IGF2 SNPs, 15 were genotyped using KASPar assays, which are competitive
allele-speciﬁc PCR SNP genotyping assays using FRET quencher cassette
oligonucleotides (designed and performed by KBioscience, Hoddesdon, U.K.).
The remaining two SNPs were genotyped by PCR restriction fragment–length
polymorphism analysis as described below.
rs11603378 was genotyped using 10 ng genomic DNA, 1 3 NH4 buffer
(Bioline, London, U.K.), 200 mmol/L each deoxyribonucleotide triphosphate,
2.5 mmol/L magnesium, 0.6 pmol/L each oligonucleotide primer (forward
59-CCAGGCCACATAGTGTAAGTCTGGAA-39 and reverse 59-CCAGGGCGCTCCG
CGCTA-39), 10% v/v glycerol, and 0.5 units Taq DNA polymerase (Bioline) in
a total volume of 10 mL. This PCR mix was incubated at 94°C for 5 min fol-
lowed by 20 cycles of 94°C for 45 s, 64°C for 45 s (dropping 0.5°C per cycle),
and 72°C for 45 s. This was followed by 15 cycles of 94°C for 45 s, 54°C for 45 s,
and 72°C for 45 s, followed by a 10-min incubation at 72°C. This was digested for
16 h at 37°C with 1 unit of StyI (New England Biolabs, Hitchin, U.K.). Separating
the samples on a 2% w/v agarose gel by electrophoresis gave a 373 bp band for
the G allele and 287 and 86 bp bands for the T allele.
rs3741206 was genotyped using a similar method but with different primers
(forward 59-GAGCCGGGGGCCCGAGATTC-39 and reverse 59-GTGCCAGG-
GAGGCTGGGAGA-39), only 1 mmol/L magnesium and no glycerol in the PCR
mix, and annealing temperatures that were 2°C higher throughout. The PCR
products were digested by incubation for 16 h at 37°C with 1 unit of HpyCH4 V
(New England Biolabs). Separating the samples on a 2% w/v agarose gel by
electrophoresis gave a 245 bp band for the A allele and 195 and 50 bp bands
for the G allele.
All SNP genotypes (for the offspring and parents separately), with the
exception of rs3741205, were shown to be consistent with Hardy Weinberg
equilibrium (P . 0.05 using the x2 test) and had a repeat genotyping discor-
dancy rate of ,1.0%.
Placental RNA extraction and gene expression studies. Of the 420 avail-
able placentas, 29 were from pregnancies where the fetus had all four pater-
nally transmitted IGF2 alleles that were associated with higher maternal
glucose concentrations; 32 were from pregnancies where the fetus had all four
alleles that were associated with lower glucose concentrations. Of these, the
21 (higher) and 29 (lower) most recently collected placentas were used for
IGF-II protein measurements. For the transcription studies, equivalent num-
bers were 16 and 19.
While keeping the tissue frozen, three samples were cut from the basal plate
of each placenta, and the outer 3 mm of each was discarded. Samples were then
pooled before homogenization and extraction using Qiagen Tissueruptor and
RNeasy ﬁbrous mini kits as per the manufacturer’s instructions. RNA was
quantiﬁed using a Nanodrop (Labtech Ltd., Ringmer, U.K.) and the integrity
was assessed using an Agilent Bioanalyzer (Agilent Technologies, Stockport,
U.K.). Only samples with a 260/280 nm absorbance ratio .2.0 and an integrity
score .6.4 were used. Synthesis of cDNA was performed using the Bioline
cDNA Synthesis Kits according to the manufacturer’s instructions (using 2 mg
RNA per reaction, reverse transcriptase and random hexamers, and incubating
at 42°C for 30 min.). Controls containing no reverse transcriptase were
TABLE 1
Study participant demographics for the 845 family trios in the
Cambridge Baby Growth Study
Demographic
Maternal age at delivery (years) 33.5 (4.3)
Maternal height (cm) 165.9 (7.2)
Maternal prepregnancy weight (kg) 66.3 (13.5)
Maternal prepregnancy BMI (kg/m2) 24.1 (4.6)
28-week maternal fasting plasma
glucose concentration (mmol/L) 4.3 (0.6)
28-week maternal glucose plasma glucose
concentration (60 min after the
consumption of a 75-g oral glucose load)
(mmol/L) 6.8 (1.7)
Prepregnancy gravidity 1.8 (0.9)
Prepregnancy parity 0.4 (0.8)
Twin pregnancies (%) 2.0
Maternal smoking in pregnancy (%) 5.4
Gestational age at delivery (weeks) 39.8 (1.6)
Offspring ethnicity (% Caucasian) 96.9
Offspring sex (% male) 51.6
Offspring birth weight (g) 3,479 (533)
Paternal age at delivery (years) 35.4 (5.3)
Data are mean (SD) or percentages.
TABLE 2
Study participant demographics for the 315 family trios in the
Cambridge Wellbeing Study
Demographic
Maternal age at delivery (years) 33.1 (4.1)
28-week maternal glucose plasma
glucose concentration (60 min after the
consumption of a 50-g oral
glucose load) (mmol/L) 5.6 (1.4)
Prepregnancy parity 0.8 (0.8)
Twin pregnancies (%) 0*
Gestational age at delivery (weeks) 39.6 (1.3)
Offspring ethnicity (% Caucasian) 100*
Offspring sex (% male) 50.8
Offspring birth weight (g) 3,562 (495)
Data are mean (SD) or percentages. *Inclusion criteria.
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included for each sample. TaqMan Gene Expression Assays (Applied Bio-
systems, Warrington, U.K.) were purchased for various IGF2 transcripts and
the validated placental reference genes YWHAZ, TOP1, and UBC (18) (Sup-
plementary Table 1). The quantitative PCR reactions were performed using
TaqMan Universal Master Mix (Applied Biosystems) on a Stratagene Mx3005P
Real-Time PCR system (Agilent Technologies). Data were analyzed using
geNorm software (19) to check the stability of the three reference genes. M
values (geNorm software) for TOP1, UBC, and YWHAZ were 0.453, 0.542, and
0.429, respectively, with a pairwise variation value of 0.172. The resulting nor-
malization factors were used to convert the raw expression values.
IGF-II protein was extracted overnight from 400mgmechanically pulverized
placental samples in 4 mL 0.18 mol/L HCl/75% ethanol solution at 4°C. The
following morning, the samples were spun for 15 min at 12,000g at 4°C. Then
100 mL of the upper layer was carefully removed and neutralized with 100 mL 1
mol/L Tris-buffered saline pH 7.4. IGF-II contents were measured in 20 mL of
these neutralized extracts using ELISA kits according to the manufacturer’s
instructions (Stratech Scientiﬁc, Newmarket, U.K.). Extract total protein
contents were estimated by measuring their absorbance at 280 nm.
Statistical analysis. In light of the different glucose loads used in each cohort,
postload maternal glucose responses were standardized by calculating z scores
separately in each cohort (using the mean and SD for glucose concentrations
from all women in each cohort) and then analyzed as a single group of .1,100
family DNA trios with maternal glucose z scores. IGF2 SNP genotypes from
both parents and their child were used to infer parental transmission
according to Supplementary Table 2. Initial association analyses were
performed separately for each haplotype block (or SNP that was not part of
a block) using ANOVA models with maternal glucose z score or birth weight
as the dependent variable and all the fetal SNP alleles from that block as in-
dependent covariates. For haplotype blocks (or SNPs) reaching P , 0.05 in
these ANOVA models, the relevant fetal alleles were taken forward to a gen-
eral linear model containing the relevant dependent variable adjusted for
parity and offspring sex (as potential confounders) (2) for maternal glucose
z scores. Birth weight models were adjusted for gestational age, parity, and
offspring sex, which account for 25% of the variance in birth weight in our
populations. Areas under the capillary blood glucose curves were calculated
using the trapezoid rule. The critical value for statistical signiﬁcance corrected
for testing all 17 genotyped IGF2 SNPs was 0.003, calculated using the mini-
mum P value test (20), which has been shown to be robust in this type of
analysis (21). A P value of,0.017 was used to deﬁne statistical signiﬁcance for
association with speciﬁc SNPs by applying a Bonferroni correction to the use
of paternally and maternally transmitted fetal alleles and maternal genotypes.
Placental data were analyzed using the Mann-Whitney U test, with a P value of
,0.05 considered statistically signiﬁcant.
RESULTS
Haplotype block 1. Haplotype block 1 fetal alleles were
associated with maternal glucose z score (P = 0.048) but
not with offspring birth weight (P = 0.7). The paternally
transmitted fetal rs6578987 C allele was associated with
increased maternal glucose z score (P = 0.006; without
signiﬁcant interaction with offspring sex, P = 0.5) (Fig. 2).
The maternally transmitted fetal rs6578987 allele and the
rs4341514 alleles (irrespective of their parent of origin)
were not associated with maternal glucose z scores.
Haplotype block 2. Haplotype block 2 fetal alleles were
associated with maternal glucose z score (P = 0.018) but
not with offspring birth weight (P = 1.0). The paternally
transmitted fetal rs10770125 A allele was associated with
increased maternal glucose z score (P = 0.0002, with an ef-
fect size of 0.268 [95% CI 0.164–0.372] z scores,;0.4 mmol/L
glucose; there was no signiﬁcant interaction with offspring
sex, P = 0.7) (Fig. 2). In contrast, the maternally trans-
mitted fetal rs10770125 allele and all the alleles for SNPs
rs3213216, rs3741212, or rs11603378 were not associated
with maternal glucose z scores (data not shown).
Haplotype blocks 3–5. Maternal glucose z score was not
associated with fetal alleles from haplotype blocks 3 (P =
0.5), 4 (P = 0.06), or 5 (P = 0.2). In a similar manner, off-
spring birth weight was not associated with fetal alleles
from haplotype blocks 3 (P = 0.5), 4 (P = 0.8), or 5 (P = 0.2).
FIG. 1. Schematic diagram of the region of chromosome 11 genotyped in this study, showing the associated genes (IGF2, INS, and TH) and
transcripts (IGF2, INS, TH, antisense IGF2, and INS-IGF2 readthrough transcript). Exons are shown as blocks. Chromosomal position based on
National Center for Biotechnology Information Genome Reference Consortium Human genome build 36. (A high-quality color representation of
this ﬁgure is available in the online issue.)
FETAL IGF2 AND MATERNAL GLUCOSE CONCENTRATIONS
3092 DIABETES, VOL. 60, NOVEMBER 2011 diabetes.diabetesjournals.org
Other SNPs not deﬁning haplotype blocks. The pater-
nally transmitted but not the maternally transmitted fetal
rs680 A allele was associated with increased maternal
glucose z score (P = 0.01; without signiﬁcant interaction
with offspring sex, P = 0.7) (Fig. 2). Neither fetal rs680
allele was associated with offspring birth weight. None of
the fetal rs734351 alleles were associated with either ma-
ternal glucose z score or with offspring birth weight. The
paternally transmitted fetal rs7924316 T allele was asso-
ciated with increased maternal glucose z score (P = 0.01;
without signiﬁcant interaction with offspring sex, P = 0.4)
(Fig. 2), unlike the allele transmitted from the mother.
Neither fetal rs7924316 allele was associated with offspring
birth weight.
Associations in the two separate cohorts. Paternally
transmitted fetal rs10770125 was signiﬁcantly associated
with maternal glucose concentrations in both the Cambridge
Baby Growth Study (P = 0.01) and the Cambridge Wellbeing
Study (P = 0.006) (Supplementary Table 3). The other
SNPs that had signiﬁcant associations in the combined
cohort did not have signiﬁcant associations in the modestly
sized Cambridge Wellbeing Study (although the trends
were in the same direction). The one exception to this was
rs7924316, which had a stronger association in the Cambridge
Wellbeing Study (P = 0.04) than in the larger Cambridge
Baby Growth Study (P = 0.07).
Fasting plasma venous glucose and areas under the
capillary glucose curves. Paternally transmitted fetal
rs6578987, rs680, rs10770125, and rs7924316 also showed
associations with fasting plasma glucose concentrations
(P = 0.002, 0.008, 0.046, and 0.007, respectively) and areas
under the capillary glucose curves (P = 0.005, 0.026, 0.020,
and 0.059, respectively) in the Cambridge Baby Growth
Study (Supplementary Table 4).
Maternal IGF2 genotypes. None of the maternal (as
opposed to the maternally transmitted fetal) IGF2 genotypes
were associated with either their own glucose z scores or
offspring birth weights (data not shown).
Linkage disequilibrium between fetal IGF2 alleles that
were associated with maternal glucose concentrations.
There was variable but signiﬁcant linkage disequilibrium
between the four fetal SNPs whose paternally transmitted
alleles were associated with maternal glucose concentrations
(D9 = 0.81–0.96, r 2 = 0.30–0.90) (Supplementary Fig. 2).
Placental IGF2 expression and IGF-II protein content
at term. Placental IGF-II (protein) contents at birth were
raised by 39% in those placentas whose corresponding
fetal genotypes were associated with higher glucose
concentrations (P = 0.03) (Table 4). There was no signif-
icant difference in the relative expression of the IGF2
transcripts 1 or 2 or antisense IGF2 transcripts; the INS-
IGF2 readthrough transcript was undetectable in all
placentas. Relative expression of IGF2 transcript 3 was
reduced by 46% in those placentas having genotypes
associated with higher maternal glucose concentrations
(P = 0.02).
DISCUSSION
Our results show that polymorphic variation in the fetal
IGF2 gene, speciﬁcally in the copy of the gene transmitted
from the father, is associated with increased maternal
glucose concentrations in the third trimester of pregnancy.
Consistent with their expected imprinted status, we found
no associations with the maternally transmitted fetal
alleles. Neither was the maternal IGF2 genotype associ-
ated with glucose concentrations, unlike the ﬁndings in
one previous study assessing maternal IGF2 restriction
fragment–length polymorphisms in 96 women with GDM
(22). The signiﬁcant associations between paternally trans-
mitted fetal alleles and maternal glucose z scores are
unique ﬁndings, in terms of both IGF2 and ﬁnding asso-
ciations between genetic variation in paternally trans-
mitted genes and maternal glucose tolerance in pregnancy.
In one study, mothers carrying offspring with Beckwith
Wiedemann syndrome, where probands have abnormally
increased IGF2 expression (23), showed a trend toward an
increased risk of developing GDM (24). Also, in our mouse
model, we showed that pregnant mice carrying pups with
a doubling in Igf2 expression levels have worse glucose
tolerance than controls in the ﬁnal week of their 3-week
pregnancies (8). Unlike recent ﬁndings for a maternal pro-
gesterone receptor gene polymorphism (25) and peroxi-
some proliferator–activated receptor-g (26), in our study,
there was no signiﬁcant interactive effect of fetal sex on
the associations with maternal glucose concentrations,
suggesting that these associations are mediated by differ-
ent mechanisms. They are all examples of fetuses having
associations with changes in maternal glucose concen-
trations in pregnancy, however (2,3).
The kinship hypothesis suggests that paternally ex-
pressed imprinted genes will tend to boost fetal growth
and that in contrast, maternally expressed imprinted genes
will tend to limit it (5,6). The signiﬁcant associations be-
tween certain paternally transmitted fetal IGF2 alleles and
increased maternal glucose concentrations in our study
are partially consistent with the kinship hypothesis (5,6),
therefore, given that only the paternally transmitted IGF2
allele is active in fetal life and maternal glucose concen-
trations in pregnancy are linked to fetal growth (27). The
results are not fully consistent, however, because there
were no associations between any of the IGF2 fetal or
TABLE 3
IGF2 region SNPs genotyped in the Cambridge Baby Growth and
Wellbeing studies
dbSNP
Number
Position on
chromosome 11*
(bp)
Relative position
(bp)
Haplotype
block
rs6578987 2098162 0 1
rs4341514 2098179 17 1
rs680 2110210 12048 N/A
rs734351 2112789 14627 N/A
rs3213216 2114755 16593 2
rs3741212 2118434 20272 2
rs11603378 2121749 23587 2
rs10770125 2125590 27428 2
rs3741206 2126440 28278 3
rs3741205 2126460 28298 3
rs1004446 2126719 28557 3
rs4320932 2128177 30015 3
rs7924316 2130023 31861 N/A
rs3842752 2137649 39487 4
rs7483056 2147095 48933 4
rs6356 2147527 49365 5
rs10743152 2152557 54395 5
N/A SNPs were analyzed in isolation as the only genetic variants
added to the linear regression statistical models. *Chromosomal
position based on National Center for Biotechnology Information
Genome Reference Consortium Human genome build 36 (refer-
ence assembly).
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maternal variants and offspring birth weight, probably
because the effect sizes on maternal glucose concen-
trations were too small to make a detectable difference in
birth weight in our sample. Indeed, using data from the
Hyperglycemia and Adverse Pregnancy Outcome Study
(27), our largest effect size would have given an odds ratio
of only 1.11 for a birth weight above the 90th percentile.
The lack of association with birth weight is in general
agreement with other studies that have sought but not
found association between fetal IGF2 SNP variants and
birth weight (28–30), although associations have been
found in some populations (31–33). Cord blood IGF-II
protein concentrations are associated with birth weight
(12,13), but its genetic regulation is not solely due to poly-
morphic IGF2 variation because other genes in 11p15.5,
including the insulin gene variable number of tandem repeats
(34), and H19 (13) can inﬂuence it.
We found four paternally transmitted IGF2 fetal alleles
that are associated with maternal glucose concentrations
in week 28 of pregnancy. Using standard interpretations of
D9 .0.7 and/or r2 .0.3 (35,36), these four markers appear
to be in strong linkage disequilibrium with each other and
could therefore be markers of the same causal signal. The
strongest candidate that we have for this marker is pa-
ternally transmitted fetal rs10770125 (and the SNPs that it
tags, rs1003483 and rs4244808), because it gave the largest
differential in maternal glucose z scores between the two
alleles, the lowest P value, and also was the only marker
that was independently statistically signiﬁcant in both the
Cambridge Baby Growth Study and the more modestly
FIG. 2. Error bar graph showing mean (95% CI) maternal glucose concentration z scores 60 min postglucose load according to 1) paternally
transmitted and 2) maternally transmitted fetal IGF2 alleles at rs6578987, rs680, rs10770125, and rs7924316.
FETAL IGF2 AND MATERNAL GLUCOSE CONCENTRATIONS
3094 DIABETES, VOL. 60, NOVEMBER 2011 diabetes.diabetesjournals.org
sized Cambridge Wellbeing Study (Supplementary Table 3).
Human splicing ﬁnder (37) predicts that rs10770125 is
an exonic splicing or enhancer site plus a micro RNA
binding site. In a similar manner, for rs1003483 and
rs4244808, it predicts alterations in exonic splicing or en-
hancer sites, albeit with fewer potential sites than for
rs10770125. As well as all three SNPs being present in the
IGF2 and antisense IGF2 (IGF2AS) transcripts, they are
also present in the INS-IGF2 readthrough transcript. In-
deed, rs10770125 codes for a missense nonsynonymous
leucine-to-proline mutation in this readthrough transcript.
However, this transcript was undetectable in our placentas
and so is unlikely to explain the associations with maternal
glucose concentrations despite its supposed placental
expression (38). In contrast, those placentas whose ge-
notypes were associated with higher maternal glucose
concentrations had signiﬁcantly increased IGF-II protein
contents and nonsigniﬁcant increases in median mRNA
expression of IGF2 transcript variants 1 and 2 of a similar
magnitude, which may more easily explain the associations
given that in mouse models, placental Igf2 expression
relates to that of maternal hormones thought to increase
maternal glucose concentrations (38). They also had lower
expression of the IGF2 low copy number transcript variant
3, although the signiﬁcance of this is unclear because the
IGF-II isoform 2 it codes for is present at approximately
eightfold lower levels in human placenta than isoform 1
coded for by transcript variants 1 and 2 (39,40).
The limitations of our study include the relatively mod-
est size of the cohorts used. One explanation for this is the
practical difﬁculties in collecting samples from three
family members rather than just one. It should be noted
that inferring the parental origins of fetal alleles for.1,100
trios requires genotyping of .3,300 individuals. For our
primary analyses, we combined data collected from two
separate cohorts to increase statistical power because
they were recruited from patients treated at the same
hospital and so were drawn from the same geographic and
ethnic (largely Caucasian) pool. A further limitation of our
study is the lack of paternity testing, although the con-
founding effects of this are likely to be minimal as 1) pa-
ternally transmitted fetal alleles can be positively inferred
even without paternal DNA samples unless maternal and
offspring SNP genotypes are heterozygous and 2) in our
cohorts using data from 31 SNPs, DNA trio genotypes were
not consistent in only 1.5% of the cases (data not shown).
We only had maternal BMI available in a subset of family
trios (which was not different between groups inheriting
our key SNPs) and, thus, these data were not included in
the main analyses. However, we cannot totally exclude
a confounding effect of maternal BMI in those samples for
which this information was not available. In a similar
manner, we did not have details of paternal age and BMI or
maternal smoking and hypertension for all the trios, so we
cannot entirely exclude a confounding effect of these ei-
ther. The glucose load used was also different in the two
cohorts (50 g for the Cambridge Wellbeing Study and 75 g
for the Cambridge Baby Growth Study), but we overcame
this by standardizing glucose concentration z scores sep-
arately in each cohort. Furthermore, not all DNA trios
were informative because parental transmission could not
be inferred if all members of a trio were heterozygous for
a particular SNP. The statistical analyses could therefore
have been biased by informative omission from heterozy-
gous trios. This is unlikely to have had a major effect,
though, because not all heterozygous parents or children
were considered uninformative (e.g., even if both parents
were heterozygous for a particular SNP, they were con-
sidered uninformative only if their offspring were also
heterozygous). Ultimately, however, for our association of
paternally transmitted fetal rs10770125 with maternal glu-
cose concentrations or z scores, statistical signiﬁcance
was reached in the number of samples genotyped whether
or not data from our two birth cohorts were combined.
Replication in additional populations is needed to strengthen
this ﬁnding.
In conclusion, while associations with maternal genes
have been described (2), we report for the ﬁrst time as-
sociation between polymorphic variation in a paternally
transmitted fetal gene, namely, IGF2, and maternal glucose
concentrations in pregnancy. These ﬁndings are consistent
with recent ﬁndings from animal models (7,8) and support
the hypothesis that variations in fetal imprinted genes reg-
ulate the maternal availability of nutrients (3).
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